Skip to main content

Tirzepatide News

ENDO: Guidelines Developed for Pregnancy Care in Preexisting Diabetes

FRIDAY, July 18, 2025 – In a joint clinical practice guideline issued by the Endocrine Society and European Society of Endocrinology, recommendations are presented for pregnancy care in individuals...

Diabetic Women Should Be Asked About Desire For Kids At Every Doctor's Visit, Guidelines Say

FRIDAY, July 18, 2025 — Doctors should ask diabetic women at every visit about their intention to have a child, to make sure they get the appropriate care prior to conception, new guidelines say. T...

GLP-1 Receptor Agonist Use in T2D Tied to Increased Risk for GERD, GERD Complications

THURSDAY, July 17, 2025 – For patients with type 2 diabetes, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are associated with an increased risk for gastroesophageal reflux disease (GERD)...

Diet, Exercise Can Help GLP-1 Patients Who Miss Doses

TUESDAY, July 15, 2025 — It can sometimes be tough to fill prescriptions for GLP-1 drugs like Wegovy and Zepbound, given the overwhelming popularity of the breakthrough weight-loss meds. But people w...

ENDO: Superior Weight Loss Seen With Tirzepatide and Menopausal Hormone Therapy Use

TUESDAY, July 15, 2025 – In postmenopausal women with overweight or obesity receiving tirzepatide, use of menopausal hormone therapy (MHT) is associated with superior weight loss outcomes, according...

Menopause Hormone Therapy Boosts GLP-1 Drug Effectiveness, Researchers Say

MONDAY, July 14, 2025 — Good news for women of a certain age: Hormone replacement therapy for menopause appears to boost the effectiveness of GLP-1 weight loss drugs like Wegovy and Zepbound, a new s...

Degree of Weight Loss Affects Tirzepatide-Linked Cardiometabolic Risk Improvement

TUESDAY, July 1, 2025 – For adults with obesity or overweight, tirzepatide-linked improvements in cardiometabolic risk factors are associated with the degree of weight reduction, according to a...

Rival GLP-1 Weight-Loss Drug, Ecnoglutide, Emerges From China

TUESDAY, June 24, 2025 — A new Chinese-developed GLP-1 weight loss drug could prove a new competitor to blockbuster drugs Ozempic/Wegovy and Zepbound, clinical trial results show. Ecnoglutide helped p...

Few Adolescents With Obesity Prescribed Obesity Medications

FRIDAY, June 13, 2025 – Despite an increase in the prevalence of prescribing, only 0.5 percent of U.S. adolescents with obesity were prescribed an obesity medication in 2023, according to research...

Real-World Weight Loss With Semaglutide, Tirzepatide Less Than That Seen in Clinical Trials

THURSDAY, June 12, 2025 – For patients with obesity initiating pharmacotherapy with semaglutide or tirzepatide, weight loss at one year is 8.7 percent on average, which is lower than the percentages...

Real-World Results For GLP-1 Drugs Underwhelm, Study Says

WEDNESDAY, June 11, 2025 — Real-world results for blockbuster weight-loss meds like Ozempic, Wegovy and Zepbound aren’t as impressive as those promised by the drugs’ clinical trials, a new study says....

American Society of Clinical Oncology, May 31-June 3

The annual meeting of the American Society of Clinical Oncology was held from May 31 to June 3 in Chicago and hosted more than 35,000 participants, including clinicians, academicians, allied health p...

Doctors Favor CPAP, Patients Favor Tirzepatide for Comorbid Obesity, Sleep Apnea

MONDAY, June 9, 2025 – Both continuous positive airway pressure (CPAP) and tirzepatide are acceptable treatments for comorbid obesity and obstructive sleep apnea (COBOSA), with providers favoring...

CPAP Or Zepbound? Patients, Doctors Debate Sleep Apnea Treatment

MONDAY, June 9, 2025 — A clash is brewing between doctors and patients when it comes to treatment for sleep apnea in those with obesity, a new study reports. Doctors favor treatment with continuous p...

ASCO: GLP-1 Receptor Agonists May Reduce Risk for Obesity-Related Cancer, All-Cause Death

WEDNESDAY, May 28, 2025 – For adults with diabetes and obesity, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are associated with a reduced risk for obesity-related cancer compared with...

Ask a question

To post your own question to our community, sign in or create an account.

Further information

Related condition support groups

Weight Loss (Obesity / Overweight), Obstructive Sleep Apnea/Hypopnea Syndrome, Diabetes, Type 2

Related drug support groups

Mounjaro, Zepbound

Tirzepatide patient information at Drugs.com